Cargando…
Survey on the management of Pompe disease in routine clinical practice in Spain
BACKGROUND: Despite the availability of several clinical guidelines, not all health professionals use their recommendations to manage patients with Pompe disease, a rare genetic disorder involving high-impact therapy. Through several discussion meetings and a survey, the present study aimed to learn...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724265/ https://www.ncbi.nlm.nih.gov/pubmed/36471448 http://dx.doi.org/10.1186/s13023-022-02574-5 |
_version_ | 1784844373022736384 |
---|---|
author | Domínguez-González, Cristina Díaz-Marín, Carmina Juntas-Morales, Raúl Nascimiento-Osorio, Andrés Rivera-Gallego, Alberto Díaz-Manera, Jordi |
author_facet | Domínguez-González, Cristina Díaz-Marín, Carmina Juntas-Morales, Raúl Nascimiento-Osorio, Andrés Rivera-Gallego, Alberto Díaz-Manera, Jordi |
author_sort | Domínguez-González, Cristina |
collection | PubMed |
description | BACKGROUND: Despite the availability of several clinical guidelines, not all health professionals use their recommendations to manage patients with Pompe disease, a rare genetic disorder involving high-impact therapy. Through several discussion meetings and a survey, the present study aimed to learn about the management of Pompe disease in routine clinical practice in Spain, to improve clinical care in a real-life situation. RESULTS: The survey was sent to 42 healthcare professionals who manage patients with Pompe disease in their clinical practice. Although most respondents followed the clinical guidelines, clinical practice differed from the expert recommendations in many cases. Approximately 7% did not request a genetic study to confirm the diagnosis before starting treatment, and 21% considered that only two dried blood spot determinations suffice to establish the diagnosis. About 76% requested anti-GAA antibodies when there is a suspicion of lack of treatment efficacy, though a significant percentage of respondents have never requested such antibodies. According to 31% of the respondents, significant impairment of motor function and/or respiratory insufficiency is a requirement for authorizing medication at their hospital. Up to 26% waited for improvements over the clinical follow-up to maintain treatment and withdrew it in the absence of improvement since they did not consider disease stabilization to be a satisfactory outcome. CONCLUSIONS: The results highlight the lack of experience and/or knowledge of some professionals caring for patients with Pompe disease. It is necessary to develop and disseminate simple guidelines that help to apply the expert recommendations better or centralize patient follow-up in highly specialized centers. |
format | Online Article Text |
id | pubmed-9724265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97242652022-12-07 Survey on the management of Pompe disease in routine clinical practice in Spain Domínguez-González, Cristina Díaz-Marín, Carmina Juntas-Morales, Raúl Nascimiento-Osorio, Andrés Rivera-Gallego, Alberto Díaz-Manera, Jordi Orphanet J Rare Dis Research BACKGROUND: Despite the availability of several clinical guidelines, not all health professionals use their recommendations to manage patients with Pompe disease, a rare genetic disorder involving high-impact therapy. Through several discussion meetings and a survey, the present study aimed to learn about the management of Pompe disease in routine clinical practice in Spain, to improve clinical care in a real-life situation. RESULTS: The survey was sent to 42 healthcare professionals who manage patients with Pompe disease in their clinical practice. Although most respondents followed the clinical guidelines, clinical practice differed from the expert recommendations in many cases. Approximately 7% did not request a genetic study to confirm the diagnosis before starting treatment, and 21% considered that only two dried blood spot determinations suffice to establish the diagnosis. About 76% requested anti-GAA antibodies when there is a suspicion of lack of treatment efficacy, though a significant percentage of respondents have never requested such antibodies. According to 31% of the respondents, significant impairment of motor function and/or respiratory insufficiency is a requirement for authorizing medication at their hospital. Up to 26% waited for improvements over the clinical follow-up to maintain treatment and withdrew it in the absence of improvement since they did not consider disease stabilization to be a satisfactory outcome. CONCLUSIONS: The results highlight the lack of experience and/or knowledge of some professionals caring for patients with Pompe disease. It is necessary to develop and disseminate simple guidelines that help to apply the expert recommendations better or centralize patient follow-up in highly specialized centers. BioMed Central 2022-12-05 /pmc/articles/PMC9724265/ /pubmed/36471448 http://dx.doi.org/10.1186/s13023-022-02574-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Domínguez-González, Cristina Díaz-Marín, Carmina Juntas-Morales, Raúl Nascimiento-Osorio, Andrés Rivera-Gallego, Alberto Díaz-Manera, Jordi Survey on the management of Pompe disease in routine clinical practice in Spain |
title | Survey on the management of Pompe disease in routine clinical practice in Spain |
title_full | Survey on the management of Pompe disease in routine clinical practice in Spain |
title_fullStr | Survey on the management of Pompe disease in routine clinical practice in Spain |
title_full_unstemmed | Survey on the management of Pompe disease in routine clinical practice in Spain |
title_short | Survey on the management of Pompe disease in routine clinical practice in Spain |
title_sort | survey on the management of pompe disease in routine clinical practice in spain |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724265/ https://www.ncbi.nlm.nih.gov/pubmed/36471448 http://dx.doi.org/10.1186/s13023-022-02574-5 |
work_keys_str_mv | AT dominguezgonzalezcristina surveyonthemanagementofpompediseaseinroutineclinicalpracticeinspain AT diazmarincarmina surveyonthemanagementofpompediseaseinroutineclinicalpracticeinspain AT juntasmoralesraul surveyonthemanagementofpompediseaseinroutineclinicalpracticeinspain AT nascimientoosorioandres surveyonthemanagementofpompediseaseinroutineclinicalpracticeinspain AT riveragallegoalberto surveyonthemanagementofpompediseaseinroutineclinicalpracticeinspain AT diazmanerajordi surveyonthemanagementofpompediseaseinroutineclinicalpracticeinspain |